Abstract

Tumor-associated myeloid-derived cells (MDCs) significantly impact cancer prognosis and treatment responses due to their remarkable plasticity and tumorigenic behaviors. Here, we integrate single-cell RNA-sequencing data from different cancer types, identifying 29 MDC subpopulations within the tumor microenvironment. Our analysis reveals abnormally expanded MDC subpopulations across various tumors and distinguishes cell states that have often been grouped together, such as TREM2+ and FOLR2+ subpopulations. Using deconvolution approaches, we identify five subpopulations as independent prognostic markers, including states co-expressing TREM2 and PD-1, and FOLR2 and PDL-2. Additionally, TREM2 alone does not reliably predict cancer prognosis, as other TREM2+ macrophages show varied associations with prognosis depending on local cues. Validation in independent cohorts confirms that FOLR2-expressing macrophages correlate with poor clinical outcomes in ovarian and triple-negative breast cancers. This comprehensive MDC atlas offers valuable insights and a foundation for futher analyses, advancing strategies for treating solid cancers.

Tumour-associated myeloid cells have been linked to patient outcome and treatment response in multiple cancer types. Here, the authors use deconvolution of single cell RNA-sequencing data to identify myeloid populations which are prognostic across cancer types.

Details

Title
Single-cell resolution characterization of myeloid-derived cell states with implication in cancer outcome
Author
Guimarães, Gabriela Rapozo 1   VIAFID ORCID Logo  ; Maklouf, Giovanna Resk 1 ; Teixeira, Cristiane Esteves 1   VIAFID ORCID Logo  ; de Oliveira Santos, Leandro 1 ; Tessarollo, Nayara Gusmão 1   VIAFID ORCID Logo  ; de Toledo, Nayara Evelin 1 ; Serain, Alessandra Freitas 1 ; de Lanna, Cristóvão Antunes 1   VIAFID ORCID Logo  ; Pretti, Marco Antônio 1   VIAFID ORCID Logo  ; da Cruz, Jéssica Gonçalves Vieira 1 ; Falchetti, Marcelo 2   VIAFID ORCID Logo  ; Dimas, Mylla M. 2   VIAFID ORCID Logo  ; Filgueiras, Igor Salerno 3   VIAFID ORCID Logo  ; Cabral-Marques, Otavio 4 ; Ramos, Rodrigo Nalio 5   VIAFID ORCID Logo  ; de Macedo, Fabiane Carvalho 6 ; Rodrigues, Fabiana Resende 6 ; Bastos, Nina Carrossini 6 ; da Silva, Jesse Lopes 7   VIAFID ORCID Logo  ; Lummertz da Rocha, Edroaldo 2   VIAFID ORCID Logo  ; Chaves, Cláudia Bessa Pereira 8   VIAFID ORCID Logo  ; de Melo, Andreia Cristina 7 ; Moraes-Vieira, Pedro M. M. 9   VIAFID ORCID Logo  ; Mori, Marcelo A. 10   VIAFID ORCID Logo  ; Boroni, Mariana 1   VIAFID ORCID Logo 

 Brazilian National Cancer Institute (INCA), Laboratory of Bioinformatics and Computational Biology, Division of Experimental and Translational Research, Rio de Janeiro, Brazil (GRID:grid.419166.d) 
 Federal University of Santa Catarina, Department of Microbiology, Immunology, and Parasitology, Florianópolis, Brazil (GRID:grid.411237.2) (ISNI:0000 0001 2188 7235) 
 University of São Paulo,(USP), Department of Immunology, Institute of Biomedical Sciences, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722) 
 University of São Paulo,(USP), Department of Immunology, Institute of Biomedical Sciences, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722); Instituto D’Or de Ensino e Pesquisa, São Paulo, Brazil (GRID:grid.472984.4); University of São Paulo (USP), Department of Medicine, Division of Molecular Medicine, Laboratory of Medical Investigation 29, School of Medicine, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722) 
 University of São Paulo,(USP), Department of Immunology, Institute of Biomedical Sciences, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722); Instituto D’Or de Ensino e Pesquisa, São Paulo, Brazil (GRID:grid.472984.4); University of São Paulo (USP), Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Departament of Hematology and Cell Therapy, Hospital das Clínicas HCFMUSP, School of Medicine, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722) 
 Brazilian National Cancer Institute (INCA), Division of Pathology, Rio de Janeiro, Brazil (GRID:grid.419166.d) 
 Brazilian National Cancer Institute (INCA), Division of Clinical Research and Technological Development, Rio de Janeiro, Brazil (GRID:grid.419166.d) 
 Brazilian National Cancer Institute (INCA), Division of Clinical Research and Technological Development, Rio de Janeiro, Brazil (GRID:grid.419166.d); Brazilian National Cancer Institute (INCA), Gynecologic Oncology Section, Rio de Janeiro, Brazil (GRID:grid.419166.d) 
 Universidade Estadual de Campinas, Laboratory of Immunometabolism, Department of Genetics, Evolution, Microbiology, and Immunology, Institute of Biology, Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494); Universidade Estadual de Campinas, Obesity and Comorbidities Research Center (OCRC), Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494); Universidade Estadual de Campinas, Experimental Medicine Research Cluster (EMRC), Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494) 
10  Universidade Estadual de Campinas, Obesity and Comorbidities Research Center (OCRC), Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494); Universidade Estadual de Campinas, Experimental Medicine Research Cluster (EMRC), Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494); Universidade Estadual de Campinas, Laboratory of Aging Biology, Department of Biochemistry and Tissue Biology, Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494) 
Pages
5694
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3076468688
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.